147 related articles for article (PubMed ID: 31821352)
1. Isobaric mass tagging and triple quadrupole mass spectrometry to determine lipid biomarker candidates for Alzheimer's disease.
Tokuoka SM; Kita Y; Shimizu T; Oda Y
PLoS One; 2019; 14(12):e0226073. PubMed ID: 31821352
[TBL] [Abstract][Full Text] [Related]
2. Lipidomic alterations in lipoproteins of patients with mild cognitive impairment and Alzheimer's disease by asymmetrical flow field-flow fractionation and nanoflow ultrahigh performance liquid chromatography-tandem mass spectrometry.
Kim SH; Yang JS; Lee JC; Lee JY; Lee JY; Kim E; Moon MH
J Chromatogr A; 2018 Sep; 1568():91-100. PubMed ID: 30007793
[TBL] [Abstract][Full Text] [Related]
3. Optimized sample preparation and data analysis for TMT proteomic analysis of cerebrospinal fluid applied to the identification of Alzheimer's disease biomarkers.
Weiner S; Sauer M; Visser PJ; Tijms BM; Vorontsov E; Blennow K; Zetterberg H; Gobom J
Clin Proteomics; 2022 May; 19(1):13. PubMed ID: 35568819
[TBL] [Abstract][Full Text] [Related]
4. Discovery and Confirmation of Diagnostic Serum Lipid Biomarkers for Alzheimer's Disease Using Direct Infusion Mass Spectrometry.
Anand S; Barnes JM; Young SA; Garcia DM; Tolley HD; Kauwe JSK; Graves SW
J Alzheimers Dis; 2017; 59(1):277-290. PubMed ID: 28598845
[TBL] [Abstract][Full Text] [Related]
5. Isobaric Quantification of Cerebrospinal Fluid Amyloid-β Peptides in Alzheimer's Disease: C-Terminal Truncation Relates to Early Measures of Neurodegeneration.
Rogeberg M; Almdahl IS; Wettergreen M; Nilsson LN; Fladby T
J Proteome Res; 2015 Nov; 14(11):4834-43. PubMed ID: 26452689
[TBL] [Abstract][Full Text] [Related]
6. PiB-PET Imaging-Based Serum Proteome Profiles Predict Mild Cognitive Impairment and Alzheimer's Disease.
Kang S; Jeong H; Baek JH; Lee SJ; Han SH; Cho HJ; Kim H; Hong HS; Kim YH; Yi EC; Seo SW; Na DL; Hwang D; Mook-Jung I
J Alzheimers Dis; 2016 Jul; 53(4):1563-76. PubMed ID: 27392853
[TBL] [Abstract][Full Text] [Related]
7. Plasma Proteomic Profiles of Cerebrospinal Fluid-Defined Alzheimer's Disease Pathology in Older Adults.
Dayon L; Wojcik J; Núñez Galindo A; Corthésy J; Cominetti O; Oikonomidi A; Henry H; Migliavacca E; Bowman GL; Popp J
J Alzheimers Dis; 2017; 60(4):1641-1652. PubMed ID: 29125490
[TBL] [Abstract][Full Text] [Related]
8. From brain to food: analysis of phosphatidylcholins, lyso-phosphatidylcholins and phosphatidylcholin-plasmalogens derivates in Alzheimer's disease human post mortem brains and mice model via mass spectrometry.
Grimm MO; Grösgen S; Riemenschneider M; Tanila H; Grimm HS; Hartmann T
J Chromatogr A; 2011 Oct; 1218(42):7713-22. PubMed ID: 21872257
[TBL] [Abstract][Full Text] [Related]
9. Plasma gelsolin is decreased and correlates with rate of decline in Alzheimer's disease.
Güntert A; Campbell J; Saleem M; O'Brien DP; Thompson AJ; Byers HL; Ward MA; Lovestone S
J Alzheimers Dis; 2010; 21(2):585-96. PubMed ID: 20571216
[TBL] [Abstract][Full Text] [Related]
10. Multiple reaction monitoring assay based on conventional liquid chromatography and electrospray ionization for simultaneous monitoring of multiple cerebrospinal fluid biomarker candidates for Alzheimer's disease.
Choi YS; Lee KH
Arch Pharm Res; 2016 Mar; 39(3):390-7. PubMed ID: 26404792
[TBL] [Abstract][Full Text] [Related]
11. Analyzing Cerebrospinal Fluid Proteomes to Characterize Central Nervous System Disorders: A Highly Automated Mass Spectrometry-Based Pipeline for Biomarker Discovery.
Núñez Galindo A; Macron C; Cominetti O; Dayon L
Methods Mol Biol; 2019; 1959():89-112. PubMed ID: 30852817
[TBL] [Abstract][Full Text] [Related]
12. Discovery and Subsequent Confirmation of Novel Serum Biomarkers Diagnosing Alzheimer's Disease.
Shah DJ; Rohlfing F; Anand S; Johnson WE; Alvarez MT; Cobell J; King J; Young SA; Kauwe JS; Graves SW
J Alzheimers Dis; 2016; 49(2):317-27. PubMed ID: 26484917
[TBL] [Abstract][Full Text] [Related]
13. Fatty acid analysis of blood plasma of patients with Alzheimer's disease, other types of dementia, and cognitive impairment.
Conquer JA; Tierney MC; Zecevic J; Bettger WJ; Fisher RH
Lipids; 2000 Dec; 35(12):1305-12. PubMed ID: 11201991
[TBL] [Abstract][Full Text] [Related]
14. Phenylmethanesulfonyl fluoride pretreatment stabilizes plasma lipidome in lipidomic and metabolomic analysis.
Wang X; Gu X; Song H; Song Q; Gao X; Lu Y; Chen H
Anal Chim Acta; 2015 Sep; 893():77-83. PubMed ID: 26398425
[TBL] [Abstract][Full Text] [Related]
15. Ion-trap tandem mass spectrometric analysis of Amadori-glycated phosphatidylethanolamine in human plasma with or without diabetes.
Nakagawa K; Oak JH; Higuchi O; Tsuzuki T; Oikawa S; Otani H; Mune M; Cai H; Miyazawa T
J Lipid Res; 2005 Nov; 46(11):2514-24. PubMed ID: 16150834
[TBL] [Abstract][Full Text] [Related]
16. Untargeted lipidomics reveals progression of early Alzheimer's disease in APP/PS1 transgenic mice.
Zhang X; Liu W; Zan J; Wu C; Tan W
Sci Rep; 2020 Sep; 10(1):14509. PubMed ID: 32884056
[TBL] [Abstract][Full Text] [Related]
17. An UHPLC-MS/MS method for simultaneous quantification of human amyloid beta peptides Aβ1-38, Aβ1-40 and Aβ1-42 in cerebrospinal fluid using micro-elution solid phase extraction.
Lin PP; Chen WL; Yuan F; Sheng L; Wu YJ; Zhang WW; Li GQ; Xu HR; Li XN
J Chromatogr B Analyt Technol Biomed Life Sci; 2017 Dec; 1070():82-91. PubMed ID: 29102244
[TBL] [Abstract][Full Text] [Related]
18. Glutaminyl cyclase activity correlates with levels of Aβ peptides and mediators of angiogenesis in cerebrospinal fluid of Alzheimer's disease patients.
Bridel C; Hoffmann T; Meyer A; Durieux S; Koel-Simmelink MA; Orth M; Scheltens P; Lues I; Teunissen CE
Alzheimers Res Ther; 2017 Jun; 9(1):38. PubMed ID: 28587659
[TBL] [Abstract][Full Text] [Related]
19. A column switching ultrahigh-performance liquid chromatography-tandem mass spectrometry method to determine anandamide and 2-arachidonoylglycerol in plasma samples.
Marchioni C; de Souza ID; Grecco CF; Crippa JA; Tumas V; Queiroz MEC
Anal Bioanal Chem; 2017 May; 409(14):3587-3596. PubMed ID: 28337517
[TBL] [Abstract][Full Text] [Related]
20. Plasma protein profiling of mild cognitive impairment and Alzheimer's disease across two independent cohorts.
Muenchhoff J; Poljak A; Song F; Raftery M; Brodaty H; Duncan M; McEvoy M; Attia J; Schofield PW; Sachdev PS
J Alzheimers Dis; 2015; 43(4):1355-73. PubMed ID: 25159666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
